Dave Maki

Co-Founder at Altitude Funds LLC

Dave Maki

Dave Maki

Co-Founder at Altitude Funds LLC

Overview
Career Highlights

Altitude Funds LLC
Altitude Life Science Ventures LP

RelSci Relationships

231

Number of Boards

11

Birthday

1958

Age

61

Relationships
RelSci Relationships are individuals Dave Maki likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Director at Pulmatrix, Inc. (Inactive)

Relationship likelihood: Strong

Co-Founder at Effector Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Pulmatrix, Inc. (Inactive)

Relationship likelihood: Strong

Founding Partner at Polaris Partners

Relationship likelihood: Strong

Founding Partner at 5AM Venture Management LLC

Relationship likelihood: Strong

Managing Director at ARCH Venture Partners

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Intarcia Therapeutics, Inc.

Relationship likelihood: Strong

Manager at Sea Pharmaceuticals LLC

Relationship likelihood: Strong

Co-Founder at Altitude Funds LLC

Relationship likelihood: Strong

Paths to Dave Maki
Potential Connections via
Relationship Science
You
Dave Maki
Co-Founder at Altitude Funds LLC
Education
BS Degree
Class of 1980

CARROLL COLLEGE IS A CATHOLIC, DIOCESAN, LIBERAL ARTS COLLEGE IN THE ECUMENICAL TRADITION OF THE SECOND VATICAN COUNCIL. CARROLL COLLEGE ACKNOWLEDGES THE ROLE OF PREPARING ITS STUDENTS FOR A CAREER, AND ALSO AFFIRMS THE ROLE OF PROVIDING FOR THE EXPANSION OF THE INTELLECTUAL, IMAGINATIVE, AND SOCIAL AWARENESS OF ITS STUDENTS. CARROLL COLLEGE AFFIRMS ITS COMMITMENT TO THE PRINCIPLE OF FREEDOM OF INQUIRY. CARROLL COLLEGE IS COMMITTED TO A POLICY OF OPEN PARTICIPATION BY MEMBERS OF ALL RELIGIOUS FAITHS AND ALL PERSONS OF GOOD WILL IN THE TOTAL ACADEMIC AND SPIRITUAL EXPERIENCE OF THE COLLEGE COMMUNITY.

JD Law

The Northwestern University School of Law is an elite, private American law school in Chicago, Illinois. Located in the North Side's Streeterville, it is one of the twelve constituent schools of Northwestern University. The law school was founded in 1859 as the Union College of Law of the Old University of Chicago. The first law school established in Chicago, it became jointly controlled by Northwestern University in 1873 and fully incorporated into Northwestern in 1891. Northwestern Law is a member of the "T-14" law schools, a prestigious group of 14 schools that have national recognition.

Career History
Manager
2015 - Current
Co-Founder
2005 - Current

Altitude Funds sponsors and manages private equity partnerships on behalf of the GF Private Equity Group LLC of the Southern Ute Indian Tribe. The firm makes seed investments in such funds in partnership with experienced management teams with differentiated value-added strategies. They focus on investments in the following areas: energy, technology, software, telecommunications/media, consumer products/services, Government/defense, life sciences and distressed opportunities.

Co-Founder
Current

Altitude Life Science Ventures LP invests in companies located in the US with strong demand & growth potential, competitive advantage and strong management teams. The fund targets companies operating in the fields of energy, technology & software, telecommunications & media, consumer products & services, government & defense and life sciences. It provides financing for early stage capital requirements with an investment ranging from $1 to $2.5 million per company and also invests in follow on rounds.

Boards & Committees
Director
Current

Dharma Therapeutics, Inc., part of Marduk Solution Co. Ltd., is an American company located in Seattle, WA, that manufactures pharmaceutical products. It was founded by Steven G. Reed. Paul R. Sleath is currently the CEO of the firm. Marduk Solution Co. Ltd. acquired Dharma Therapeutics, Inc. from Pine Capital Group Ltd. on 21 Apr 14.

Director
Prior

Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA.

Director
Prior

Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Dave Maki. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Dave Maki's profile does not indicate a business or promotional relationship of any kind between RelSci and Dave Maki.